Included in the formulation
АТХ:A.01.A.A.08 Naphazoline
Pharmacodynamics:The α agonist1A- and α2A-adrenoreceptors: stimulation of α1-adrenoreceptors of the nasal mucosa and α2adrenoreceptors of arterioles. It causes constriction of the vessels, narrows the pupil, has an anti-inflammatory effect. With rhinitis facilitates nasal breathing, raises blood pressure.
Pharmacokinetics:Possible absorption with the development of systemic effects (hypertension).
Indications:Acute rhinitis, sinusitis, sinusitis. Pollinosis. Laryngitis. Eustachyte. Edema of the larynx of allergic genesis and on the background of irradiation. Hyperemia of the mucosa after operations on the upper respiratory tract. Nose bleed. Chronic conjunctivitis. Rhinoscopy (in combination with local anesthetics).
VII.H10-H13.H10.4 Chronic conjunctivitis
VII.H10-H13.H10.1 Acute atopic conjunctivitis
VIII.H65-H75.H68 Inflammation and occlusion of the auditory [Eustachian] tube
X.J00-J06.J00 Acute nasopharyngitis (runny nose)
X.J00-J06.J01 Acute Sinusitis
X.J00-J06.J04.0 Acute laryngitis
X.J30-J39.J30 Vasomotor and allergic rhinitis
X.J30-J39.J38.4 Laryngeal edema
X.J999.J999 * Diagnosis of respiratory diseases
XVIII.R00-R09.R04.0 Nose bleed
Contraindications:Closed-angle glaucoma. Arterial hypertension. Tachycardia. Severe atherosclerosis. Severe eye diseases. Diabetes. Thyrotoxicosis. Chronic rhinitis. Simultaneous administration of MAO inhibitors and a ten-day period after the end of their use. Children's age (up to 1 year). Individual intolerance.
Pregnancy and lactation:The action category for the fetus is FDA-C. The drug is used during pregnancy in the event that the potential benefit to the mother exceeds the potential risk to the fetus. Not recommended for use during breastfeeding.
Dosing and Administration:Intranasal (in each nasal passage) 1-3 drops of 0,05-0,1% solution 3-4 times a day.
Side effects:Local reactions: irritation of the mucous membrane, redness, and with prolonged use - swelling of the mucous membrane. Systemic reactions: nausea, headache, increased blood pressure, tachycardia.
Interaction:With simultaneous use, it slows the absorption of local anesthetics. Tricyclic antidepressants, maprotiline in combination with naphazoline enhance its effects.
The drug is incompatible with MAO inhibitors.
Special instructions:Naphazoline may have a resorptive effect. With prolonged use, the severity of the vasoconstrictor effect gradually decreases (the phenomenon of tachyphylaxis), it is possible atrophy of the mucosa, in connection with which it is recommended after 5-7 days of use to take a break for several days.